French National Cohort of Patients With Pediatric-onset of Autoimmune Cytopenia (OBS'CEREVANCE Cohort)

What this Trial Is About

Researchers are studying pediatric-onset autoimmune cytopenias, including Immune Thrombocytopenia (ITP), Autoimmune Hemolytic Anemia (AIHA), and Evans Syndrome, which involves two or three combined cytopenias. These rare diseases cause the immune system to destroy blood cells. This observational cohort study, coordinated by the CEREVANCE Rare Disease Centre and involving 30 French pediatric hematologic centers, aims to understand long-term health outcomes, genetic factors, and treatment effects in these patients. The study collects detailed data over many years on patients diagnosed before age 18 with these autoimmune cytopenias. It includes monitoring disease characteristics, treatment histories, adverse reactions, and immune-related symptoms. The cohort supports care, education, and research missions by maintaining an unbiased database that tracks health and treatment responses, including targeted therapies. Participants are followed regularly with health assessments every six months up to age 19, documenting treatments, side effects, and disease events. This long-term follow-up helps researchers describe disease progression and treatment impact. Data collected include genetic information and clinical outcomes, supporting research into the underlying causes and management of these rare pediatric autoimmune blood disorders.

OBS'CEREVANCE: French Cohort of Pediatric Autoimmune Cytopenia